# Ketamine Infusion in Neurologic Deficit

> **NCT02636218** · PHASE2,PHASE3 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 9 (actual)

## Conditions studied

- Subarachnoid Hemorrhage

## Interventions

- **DRUG:** Ketamine
- **DRUG:** 0.9% NaCl

## Key facts

- **NCT ID:** NCT02636218
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2021-03-31
- **Final completion:** 2023-11-15
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636218, "Ketamine Infusion in Neurologic Deficit". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02636218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*